Transactions
12
Insider / UNITED THERAPEUTICS Corp
PATUSKY CHRISTOPHER
Director at UNITED THERAPEUTICS Corp
- Company
- UNITED THERAPEUTICS Corp
- Ticker
- UTHR
- First filing on record
- December 16, 2025
- Latest trade on record
- July 22, 2026
- SEC filings
- EDGAR ↗
PATUSKY CHRISTOPHER, Director at UNITED THERAPEUTICS Corp, has disclosed 12 transactions in UTHR since December 16, 2025: 0 purchases (0 open-market buys) and 3 sales, worth about $3.2M at the reported prices. The latest was filed July 23, 2026, 1 day after the trade.
Open-market buys
0
Sales
3
Avg. disclosure lag
1.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months PATUSKY CHRISTOPHER made no purchases and 3 sales worth $2.7M, plus 9 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
PATUSKY CHRISTOPHER has traded 1 stock on record; the largest by dollars is UTHR.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 11,120 | $500K |
| S | Open-market sale | 3 | 4,910 | $2.7M |
| A | Grant or award | 1 | 2,380 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 9 | 0 | 2 · $2.2M |
| 2025 | 3 | 0 | 1 · $496K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| UTHR | Other A | July 22, 2026 | July 23, 2026 | 1d | 2,380 | — | — | derivative | Form 4 ↗ | |
| UTHR | Option / conversion M | July 9, 2026 | July 13, 2026 | 4d | 650 | — | — | derivative | Form 4 ↗ | |
| UTHR | Option / conversion M | July 9, 2026 | July 13, 2026 | 4d | 650 | — | — | Form 4 ↗ | ||
| UTHR | Option / conversion M | April 24, 2026 | April 24, 2026 | 0d | 2,910 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| UTHR | Sell S | April 24, 2026 | April 24, 2026 | 0d | 2,910 | $569 | $1.7M | 10b5-1 plan | Form 4 ↗ | |
| UTHR | Option / conversion M | April 24, 2026 | April 24, 2026 | 0d | 2,910 | $102 | $296K | 10b5-1 plan | Form 4 ↗ | |
| UTHR | Option / conversion M | April 17, 2026 | April 17, 2026 | 0d | 1,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| UTHR | Sell S | April 17, 2026 | April 17, 2026 | 0d | 1,000 | $579 | $579K | 10b5-1 plan | Form 4 ↗ | |
| UTHR | Option / conversion M | April 17, 2026 | April 17, 2026 | 0d | 1,000 | $102 | $102K | 10b5-1 plan | Form 4 ↗ | |
| UTHR | Option / conversion M | December 15, 2025 | December 16, 2025 | 1d | 1,000 | — | — | derivative | Form 4 ↗ | |
| UTHR | Sell S | December 15, 2025 | December 16, 2025 | 1d | 1,000 | $496 | $496K | Form 4 ↗ | ||
| UTHR | Option / conversion M | December 15, 2025 | December 16, 2025 | 1d | 1,000 | $102 | $102K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 23, 2026 | Form 4 | 0001231427-26-000004 | 1 | published | EDGAR ↗ |
| July 13, 2026 | Form 4 | 0001231427-26-000003 | 2 | published | EDGAR ↗ |
| April 24, 2026 | Form 4 | 0001231427-26-000002 | 3 | published | EDGAR ↗ |
| April 17, 2026 | Form 4 | 0001231427-26-000001 | 3 | published | EDGAR ↗ |
| December 16, 2025 | Form 4 | 0001231427-25-000004 | 3 | published | EDGAR ↗ |
Other insiders at UNITED THERAPEUTICS Corp
- ROTHBLATT MARTINE A Chairperson & CEO 2,506 rows
- EDGEMOND JAMES CFO AND TREASURER 466 rows
- BENKOWITZ MICHAEL PRESIDENT AND COO 287 rows
- MAHON PAUL A EVP & GENERAL COUNSEL 282 rows
- CAUSEY CHRISTOPHER Director 18 rows
- MALCOLM JAN Director 13 rows
- Thompson Tommy G Director 13 rows
- Mesa Nilda Director 10 rows
- Olian Judy D. Director 9 rows
- SULLIVAN LOUIS W Director 9 rows
Everyone on file, with contracts and lobbying under the company's name: UNITED THERAPEUTICS Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 12 | December 16, 2025 | July 23, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.